Sobi and Enable Injections collaborate on Aspaveli distribution

Swedish Orphan Biovitrum (Sobi) has partnered with Enable Injections to develop and distribute Aspaveli (pegcetacoplan) in combination with the enFuse technology. Under this global agreement, Sobi will handle distribution within its territories.

The enFuse injector, created by Enable Injections, is designed to facilitate the subcutaneous administration of Aspaveli. This innovative device aims to improve the patient's self-administration experience while minimizing the disruption to their daily lives. The enFuse technology provides a wearable and concealed needle solution for drug delivery, making it easier for patients to receive their treatment under the skin.

Aspaveli, also known as EMPAVELI, is a targeted C3 therapy. It plays a crucial role in regulating the complement cascade, a part of the immune system. Misregulation of this cascade can lead to the development and progression of serious diseases. Aspaveli is already approved for treating paroxysmal nocturnal haemoglobinuria (PNH) in the United States, European Union, and other global markets. Additionally, the therapy is being investigated for potential applications in treating rare diseases related to haematology and nephrology.

Sobi and Apellis Pharmaceuticals share the worldwide joint development rights for systemic pegcetacoplan. While Sobi holds exclusive rights for commercialization outside the United States, Apellis retains sole commercial rights within the US and also holds global rights for the drug's ophthalmological applications, which include indications for geographic atrophy.

Lydia Abad-Franch, head of medical affairs research and development and chief medical officer at Sobi, commented on the significance of the agreement with Enable Injections. She emphasized the company's commitment to advancing innovative solutions for treating rare diseases. According to Abad-Franch, this agreement represents a pivotal step in fulfilling that commitment. She believes that the partnership with Enable Injections has the potential to expand patient options, enhance their comfort, and support adherence to treatment protocols. Ultimately, this could lead to better health outcomes. By continuously improving the patient experience, Sobi aims to make a meaningful difference in the lives of those affected by rare diseases.

In a related development, Sobi received marketing authorization from the European Commission in June 2024 for Altuvoct (efanesoctocog alfa). This authorization covers the treatment and prevention of bleeds and perioperative prophylaxis in patients with haemophilia A.

This collaboration between Sobi and Enable Injections signifies a noteworthy advancement in the administration of Aspaveli, potentially offering patients a more convenient and less intrusive treatment option. By leveraging the capabilities of the enFuse technology, both companies aim to enhance the overall treatment experience for patients dealing with rare diseases.